Targeting tumor angiogenesis with histone deacetylase inhibitors.
about
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironmentTurning on the Radio: Epigenetic Inhibitors as Potential Radiopriming AgentsClinical use and applications of histone deacetylase inhibitors in multiple myelomaHDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesCurrent insights into the molecular mechanisms of hypoxic pre- and postconditioning using hypobaric hypoxiaEpigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor HypoxiaHDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion InjuryAnticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivoParadoxical regulation of hypoxia inducible factor-1α (HIF-1α) by histone deacetylase inhibitor in diffuse large B-cell lymphomaThe histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibitionA phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.Chemotaxis in cancerPhase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphomaA phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.Crosstalk between the DNA damage response, histone modifications and neovascularisation.Development of HIF-1 inhibitors for cancer therapyHistone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.Vascular endothelial growth factor receptor-2 in breast cancer.Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon.A strategy for integrating essential three-dimensional microphysiological systems of human organs for realistic anticancer drug screening.A novel mechanism involving coordinated regulation of nuclear levels and acetylation of NF-YA and Bcl6 activates RGS4 transcription.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia.Hdac-mediated control of endochondral and intramembranous ossificationHEXIM1 down-regulates hypoxia-inducible factor-1α protein stability.The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis.Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.Promoting brain remodeling to aid in stroke recovery.Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.HIF1α protein stability is increased by acetylation at lysine 709.A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.
P2860
Q24618224-6C5399BF-C671-41E9-BEE5-DE190CA56BB8Q26744212-5043E7D3-ED43-4C79-905E-2119A60D677FQ26745930-7845D826-07FD-4C41-838B-A885AE8548F0Q26766640-02EDFC00-5795-4919-9D85-BF367DBD06C5Q26777973-4E2A049C-865E-42AA-9B8C-09241893ED14Q26783014-7C8112CD-3EFD-457C-A0F7-28E9A728DF28Q27327201-8A7CEB43-455C-42AD-BBE6-4866B446C689Q28482468-9CF07242-444E-474F-9978-407DC79F8AEAQ28535447-5F7B6E18-71DF-4A26-A691-66482E612615Q28542639-17C707A5-FF54-4AED-81FC-DA2C59B7DEFAQ30538453-2E3E0B06-0759-437A-9371-3A2D377A40D2Q30578627-7B8F0F27-0A73-426A-8C81-51A09E3CA5EBQ33394023-D6D343D5-E318-49F6-B28A-583B7C787C67Q33419840-2B34E001-278E-4E40-BC63-257A58A8FD93Q33420276-637979B5-2200-4605-8214-17D1809383A7Q33439519-7FEC705B-899A-4D45-8D8E-5B1FAF8C5F0AQ33439523-8DB4ADB8-29AA-4920-A886-40D061616163Q33639330-08E26EEC-BC39-4BDC-B551-FFD9CA0D43FDQ33703381-C0EF64CE-3E74-4093-BFB4-9689C68498FDQ33705588-66FDA192-3BB8-4966-B8D2-45AEDAA10BA9Q33829390-275AEC01-45A2-4128-9B19-BF301A810A3CQ33912620-87C9915C-D58F-4B6C-80F7-85FFF6D146B0Q34009114-ADE408E1-C622-43E1-8BA7-C7DE851274B0Q34143251-A3ECE6D2-FCF4-449A-ACE9-96F913451CC5Q34144764-57FE1CC4-DE73-476A-B01C-7FDB9B42F8F9Q34224278-5ED1541A-56D1-45FD-82D5-866847DDE2FDQ34371189-75711099-3A19-4DD2-8F43-CA770C2ECD1DQ34399444-0FD47A92-48CC-4014-A579-A0A0721E3836Q35108007-E26CF84A-7748-4B2C-90C7-7923EAB86927Q35434188-BA742622-C685-4024-B243-C8F221FF678EQ35516124-B81D0824-03B8-4183-8603-68BC20A40A87Q35556841-883374E1-DD4B-49E3-A95D-84FA4E5F3ECDQ35602354-AEFDEB9A-84FE-45C3-ACA4-7FC26BB30E63Q35749723-4AA0EF99-BD08-464C-8F6A-3A03067DCD48Q35895346-025A622E-9A8E-456B-B36E-FD2254209F16Q35953399-28AFF7B7-D94B-4032-9332-E3A0730723EAQ36052807-47F086EA-0F5C-48DB-89B5-6B70DBA2D9CFQ36282749-BD00549A-0077-407B-803C-7EFB10E5C78BQ36318890-7D17F643-6DDF-4D0E-BA39-C784DEA99E28Q36337623-FD809660-153B-4C1C-A488-7DBD7121182B
P2860
Targeting tumor angiogenesis with histone deacetylase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@en
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@nl
type
label
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@en
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@nl
prefLabel
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@en
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@nl
P2093
P2860
P1433
P1476
Targeting tumor angiogenesis with histone deacetylase inhibitors.
@en
P2093
Hans Hammers
Leigh Ellis
Roberto Pili
P2860
P304
P356
10.1016/J.CANLET.2008.11.012
P407
P577
2008-12-25T00:00:00Z